THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

A novel type of aqueous dispersible ultrathin layered double hydroxide nanosheets for in vivo bioimaging and drug delivery

Citation for published version:

Yan, L, Zhou, M, Zhang, X, Huang, L, Chen, W, Roy, VAL, Zhang, W & Chen, X 2017, 'A novel type of aqueous dispersible ultrathin layered double hydroxide nanosheets for in vivo bioimaging and drug delivery', *ACS Applied Materials & Interfaces*. <https://doi.org/10.1021/acsami.7b05294>

Digital Object Identifier (DOI):

[10.1021/acsami.7b05294](https://doi.org/10.1021/acsami.7b05294)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

ACS Applied Materials & Interfaces

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Size Controllable and Surface Tunable Zeolitic Imidazolate Framework-8 (ZIF-8)-Poly(acrylic acid sodium salt) (PAAS) Nanocomposites for pH Responsive Drug Release and Enhanced *In Vivo* Cancer Treatment

Li Yan,^{▽,†} Xianfeng Chen,^{*,||} Zhigang Wang,⁺ Xiujuan Zhang,[‡] Xiaoyue Zhu,[†] Mengjiao Zhou,[‡] Wei Chen,[†] Longbiao Huang,[†] Vellaisamy A. L. Roy,[†] Peter K.N. Yu, Guangyu Zhu,⁺ Wenjun Zhang^{*,†}

[▽] Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics (SIIA), Chengdu University, Chengdu, Sichuan, PR China

^{||} Institute for Bioengineering, School of Engineering, The University of Edinburgh, Mayfield Road, Edinburgh EH9 3JL, United Kingdom

[†] Center of Super-Diamond and Advanced Films (COSDAF) and Department of Materials Science and Engineering, City University of Hong Kong, Hong Kong SAR

[§] Department of Physics, City University of Hong Kong, Hong Kong SAR

[‡] Functional Nano & Soft Materials Laboratory (FUNSOM) and Collaborative Innovation Center of Suzhou Nano Science and Technology, Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, Jiangsu, PR China

⁺ Department of Chemistry, City University of Hong Kong, Hong Kong SAR

Keywords: Metal-organic frameworks; nanomaterials; ZIF-8; nanocomposites; drug delivery

Abstract

Nanoscale size controllable and surface modifiable Zeolitic Imidazolate Framework-8 (ZIF-8)-Poly(acrylic acid sodium salt) (PAAS) nanocomposites are fabricated by employing PAAS nanospheres as a soft template. These ZIF-8-PAAS nanocomposites have different sizes ranging from 30 to 200 nm and exhibit different crystallinity, and pH sensitivity. These nanocomposites can be employed as vectors to deliver doxorubicin (DOX) for anticancer therapy, leading to greatly enhanced drug therapeutic efficacy when tested in cell lines and mice model. Systematic toxicity investigation including hematoxylin and eosin staining analysis of tumor and major organs, hematology analysis and blood chemistry analysis indicates that the nanocomposites possess high biocompatibility. This work provides a strategy to make metal-organic frameworks (MOFs) nanocomposites with size tunability in nanoscale and flexible surface modification for various applications.

1. Introduction

Crystalline metal-organic frameworks (MOFs) are fabricated by reticular synthesis, in which strong bonds are formed between metal ions (inorganic) and organic linker molecules.^{1,2} As an emerging crystalline material, MOFs exhibit up to 90% free volume porosity and possess a surface area of over 6000 m²/g.³ With extraordinary flexibility of selection of organic and inorganic components (more than 20,000 kinds), MOFs can be rationally tuned with versatile structure, surface area, pore size and property.⁴⁻⁷ Because of these superior characteristics, MOFs have been widely used for air purification,⁸⁻¹⁰ gas separations/storage,¹¹⁻¹⁴ chemical sensors,^{15, 16} heterogeneous catalysis,¹⁷⁻²⁰ and biomedical engineering²¹⁻²⁸.

For many applications, it is of great importance to rationally design MOFs with optimal surface chemistry and size tunability. Taking drug delivery as an example, MOFs were first used as a drug carrier in 2006.^{29, 30} Since then, MOFs have been developed to nanoregime of below 200 nm for improved drug delivery and bioimaging because materials within this size range can have high cellular uptake and long blood-circulation time^{31, 32} and these make them good candidates as drug carriers.³³⁻³⁸ Despite the progress in recent years of using nanoscale MOFs (NMOFs) for drug delivery, negligible work has been reported to produce size controllable NMOFs. Very recently, Park *et al.* reported to produce size controllable (30-190 nm) Zr(IV)-based porphyrinic MOFs by adjusting the concentration of reactant benzoic acid. The results demonstrated that the MOFs with a size of 90 nm have significantly higher cellular uptake and *in vivo* photodynamic therapy efficacy when used to deliver a photosensitizer than those of other sizes.³⁹ However, the specific parameters controlling the size of MOFs need to be tuned for each type of material. Beyond size controllability, the surface of nanomaterials plays an important role in biological and medical applications. Currently, stabilization of MOFs in aqueous solution is predominantly relying on surface coating, but the conventional polymer

or silica coating may block the pores on the surface of MOFs, leading to decrease of porosity and correspondingly drug loading capacity.⁴⁰

To address these bottlenecks of making size controllable and surface tunable NMOFs for efficient drug delivery, herein, we propose a method of employing poly(acrylic acid sodium salt) (PAAS) nanospheres as a soft template to produce size controllable and surface modifiable zeolitic imidazolate framework-8 (ZIF-8)-poly(acrylic acid sodium salt) (PAAS) nanocomposites. In this unique approach, we hypothesize that the particle size can be precisely controlled by the molecules weight of PAAS soft template; and instead of directly modifying MOFs for stabilization, the surface modification may be constructed on the PAAS template. To confirm our hypothesis, we systematically studied the approach of using PAAS as templates for synthesizing NMOFs with controllable sizes of below 200 nm and establishing desirable surface modification on PAAS. Through extensive studies, we found that surface modification molecules should be conjugated to PAAS first and then use the conjugated polymer as a template for MOFs growth. In this way, NMOFs with high stability and cancer cell targeting ability can be conveniently synthesized. Because surface modification was performed to the PAAS template, it is expected that the high porosity of NMOFs and corresponding drug loading capacity can be retained without being negatively affected by surface modification. To the best of our knowledge, such an approach of using PAAS of different molecular weights to produce NMOFs with size controllability and desirable surface modification has not been reported. After successful preparation of NMOFs, the size, morphology, structure, drug loading and release under different conditions, *in vitro* cancer cell killing efficiency, and *in vivo* tumor inhibition rate and biosafety profiles were investigated in detail. The experimental results demonstrate that these NMOFs possess superior characteristics of high drug loading capacity, pH responsive drug release, excellent tumor inhibition efficacy, and great biocompatibility. Overall, this soft-template method provides a powerful approach to fabricate size and surface controllable NMOFs for high performance applications.

2. Experimental section

2.1 Materials and Characterization

PAAS ($M_w=20k$), isopropyl alcohol and methanol were purchased from International Laboratory (U.S.A.). $Zn(NO_3)_2$ and 2-methylimidazole were ordered from Acros (U.S.A.). PAAS ($M_w=8K$), PAAS ($M_w=1.2K$) and polyethylene glycol (PEG)-Amine ($M_w=5000$) were bought from Sigma-Aldrich (U.S.A.). Doxorubicin (DOX) was from Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd (China). Dulbecco's modified eagle medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline (PBS), MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), penicillin/streptomycin, Hoechst 33342 were obtained from Life Technologies (U.S.A.). 96-well cell culture plates and cell culture dishes were obtained from Corning (U.S.A.). Zeta potential and size distribution were measured by Zetasizer (Malvern). Transmission electron microscopy (TEM) and high-resolution transmission electron microscopy (HRTEM) images were taken on Technai 12 (Philips) and JEOL JEM 2100F, respectively. Scanning electron microscopy (SEM) images were taken on FEG SEM-XL30. Powder X-ray diffraction (XRD) patterns were collected with D2 Phaser X-ray diffraction using Cu-K α radiation.

2.2 PAAS Nanosphere Fabrication

PAAS (M_w 1.2K, 8K and 20K) solutions were first diluted to 0.2 g/mL and then 200 μ L of the diluted PAAS solutions (M_w 1.2K, 8K and 20K) were added separately into 4 mL of Mini-Q water (18.2 m Ω) with 5 minutes stirring. Subsequently, 20, 40, and 80 mL of isopropyl alcohol were added into PAAS solutions with molecular weights of 1.2, 8, and 20K, respectively with magnetic stirring for making different sizes of PAAS templates.

2.3 ZIF-8-PAAS Nanocomposites Fabrication

The as-prepared PAAS nanospheres were mixing with 6.7 mL of 0.1M $Zn(NO_3)_2$ in methanol solution under stirring for 5 minutes. Then, the mixture was centrifuged at 2000, 4000, and 6000 rpm for PAAS with M_w 1.2K, 8K and 20K, respectively. Next, the precipitated PAA-

Zn nanospheres were re-dispersed in 20 mL of methanol, followed by addition of 20 mL of 20 mg/mL 2-methylimidazole in methanol under stirring. Finally, the solution was subjected to reaction at 70 °C for 12 hours.

2.4 PEG Modified ZIF-8 Nanocomposites Fabrication

First, 300 μ L of 0.2 g/mL PAAS (Mw 8K) solution and 1.5 mL of 2 mg/mL PEG-Amine were sequentially added into 1.5 mL of Mini-Q water (18.2 m Ω), followed by overnight stirring in presence of EDC as a catalyst. Second, 3 mL of Mini-Q water and 24 mL of isopropyl alcohol were added into the solution with magnetic stirring. Third, 8 mL of 0.1M Zn(NO₃)₂ in methanol solution was added and stirred for 5 minutes. Fourth, the mixture was centrifuged at 10000 rpm for 30 minutes. Fifth, the precipitation was re-dispersed in 4 mL of methanol, followed by addition of 16 mL of 20 mg/mL 2-methylimidazole in methanol under active stirring. Finally, the solution was subjected to reaction at 70 °C for 12 hours.

2.5 Drug Loading Capacity and Loading Efficiency

400, 200, 100, 50 and 25 μ L of 2 mg/mL ZIF-8 NMOFs nanocomposites solution were added into 200 μ L of 2 mg/mL DOX solution, and the mixture was under stirring for 24 hours. The amount of drug loading was determined from the absorbance differences (@480nm) of DOX in the solution before and after mixing with ZIF-8 NMOFs nanocomposites. Loading capacity and loading efficiency were calculated by following equations: (1) Loading capacity = $(W_t - W_f) / W_n * 100\%$; (2) Loading efficiency = $(W_t - W_f) / W_t * 100\%$; Where W_t is the total DOX in solution; W_f the free DOX after loading; W_n the weight of ZIF-8 NMOFs nanocomposites.

2.6 In Vitro DOX Release Profile

DOX loaded ZIP-8 NMOFs nanocomposites were added into 2 mL of buffer solution (pH=7.4 and pH=5) placed on a shaking water bath at 37 °C. After different time intervals, 120

μL of the buffer solution was collected and the amount of DOX release was measured by absorbance at 480 nm.

2.7 Fluorescence Microscopy

HeLa cell suspension was seeded onto a sterile glass coverslip in a 35 mm tissue culture dish for 24 hours. Then the cell culture medium was replaced with a fresh medium containing DOX loaded ZIF-8 NMOFs nanocomposites (10 wt% DOX) at DOX concentration of 4 $\mu\text{g/mL}$. At 4 hours after incubation, the nuclei were stained by Hoechst 33342, and the coverslip was mounted onto a glass slide for fluorescence microscopy.

2.8 Cell viability measurement

HeLa cells were washed twice with PBS. HeLa cells suspended in DMEM (with 10% FBS, 1% penicillin/streptomycin) were plated into 96-well plates (100 μL DMEM, and 1,500-3,000 cells per well). The cells were incubated at 37 °C for 24 hours before further treatment. Then, another 100 μL DMEM containing various concentrations of DOX, ZIF-8 NMOFs nanocomposites and DOX loaded ZIF-8 NMOFs nanocomposites were added into 96-well plates for additional 48 and 72 hours incubation. After incubation, the original medium in each well was removed. Subsequently, 180 μL of DMEM (without FBS) and 20 μL of MTT stock solution (5 mg/ mL in PBS) were added and incubated for 4 hours. Then the medium containing MTT was completely removed, followed by adding 200 μL of DMSO to each well. Cell viabilities were determined by reading the absorbance of the plates at 540 nm using a BioTek Powerwave XS microplate reader.

2.9 *In vivo* cancer therapy

Tumor model was developed by injection of 4T1 cells to Balb/C mice (2.5×10^6 4T1 cells in 100 μL of PBS). At 7 days after inoculation of the cancer cells, the mice were randomly divided into 4 groups $n=4$ (defined as treatment Day 1). Then 200 μL of different drug formulations at a dose of 2.5 mg/mL DOX (referred to as MOF-DOX PEG, MOF-DOX and DOX) and PBS solution were injected into the different groups of mice via the tail vein on

treatment Day 1, 7, 13 and 19. The tumor size and body weight were monitored at 3 days interval until Day 22. The tumor size was calculated according to the equation: Volume = (Tumor length)*(Tumor width)²/2. Then, major organs including heart, liver, spleen, lung, and kidney as well as tumor were harvested. All tissues were fixed in a 10% formalin solution, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for analysis. All experiments were performed in compliance with the National Act on the Use of Experimental Animals (China) and the guidelines issued by Sichuan Province and Chengdu University. All experiments were approved by the Animal Ethics Committee of Chengdu University.

3. Results and Discussion

3.1 ZIF-8 NMOFs Nanocomposites Preparation and Characterization

In our study, PAAS nanospheres were synthesized by a deionized water-isopropyl alcohol approach.⁴¹ PAAS with three different molecular weights (M_w) of 1.2K, 8K and 20K were chosen in the preparation. We found that PAAS nanospheres of different sizes of 105, 79 and 33 nm were formed by self-assembly from PAAS with M_w of 1.2K, 8K and 20K, respectively. The sizes of nanospheres were measured by dynamic light scattering (DLS). (Supporting Figure S1,) SEM also confirms that PAAS nanospheres sizes are around 80 and 35 nm for PAAS with M_w of 8K and 20K, respectively. (Supporting Figure S2 and Figure S3) Because Zn^{2+} has higher affinity towards $-COO^-$ groups in PAAS polymer chains than Na^+ , PAAS nanospheres were mixed with $Zn(NO_3)_2$ at room temperature for 5 min so that Zn^{2+} could replace Na^+ . (Scheme 1) The as-prepared PAA-Zn nanospheres were then reacted with 2-methylimidazole (2-MIMs) to form ZIF-8-PAAS crystal using the Zn^{2+} adsorbed on PAA-Zn nanospheres as Zn source. The size of ZIF-8-PAAS nanocomposites can be controlled from 200 and 90 to 30 nm by using PAAS nanosphere templates prepared from PAAS molecules with M_w of 1.2K, 8K and 20K, respectively. Depending on the molecular weight of the used PAAS, the produced

nanocomposites are denoted as ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K). The corresponding TEM images are presented in Figure 1a-c. The SEM images in Supporting Figure S4 show that ZIF-8 NMOFs nanocomposites fabricated from different PAAS nanospheres possess similar morphology. The sizes of these different ZIF-8 NMOFs nanocomposites were also confirmed by DLS analysis, which shows the diameters of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) particles are approximately 190, 98 and 46 nm, respectively. (Supporting Figure S5) The obtained ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites exhibit negative charge because of -COO^- groups in the PAAS, which was measured by DLS analysis. (Supporting Figure S6) The Fourier transform infrared spectroscopy (FTIR) spectra show carbonyl stretching vibration of -COO^- at 1580 cm^{-1} and stretching vibration of -COOH at 1717 cm^{-1} , which confirms the existence of -COO^- groups in the nanocomposites. (Supporting Figure S7)

Scheme 1. Schematic illustration of the approach of synthesizing ZIF-8 NMOFs nanocomposites using PAAS as a soft template.

Figure 1. a-c) TEM and d-f) HRTEM images of (a, d) ZIF-8 (1.2K), (b, e) ZIF-8 (8K), and (c, f) ZIF-8 (20K) NMOFs nanocomposites.

To determine the crystal structure of ZIF-8 NMOFs nanocomposite, XRD was performed. (Supporting Figure S8) From the XRD pattern, one can observe that the diffraction patterns of ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites have matched characteristic peaks, suggesting the formation of ZIF-8 crystals. The peaks of the XRD pattern of ZIF-8 (20K) are much sharper and stronger in intensity than those of ZIF-8 (1.2K) and ZIF-8 (8K). This indicates that ZIF-8 (20k) NMOFs nanocomposites possess higher crystallinity than ZIF-8 (8K) and ZIF-8 (1.2K) ones. To further investigate the difference in crystallinity, HRTEM was carried out. (Figure 1d-f and Supporting Figure S9) From the results, we can find that ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) nanocomposites contain crystalline region and amorphous area. Instead, ZIF-8 nanocrystals of a few nanometers are well-dispersed within the PAAS matrix. It is worth noting that, from the HRTEM images, ZIF-8 (20K) NMOFs nanocomposites possesses more well-aligned and larger crystalline region than ZIF-8 (8K), and ZIF-8 (1.2K) ones, which is in correspondence with the XRD results. Therefore, we can conclude that our method is able to control the crystallinity of fabricated ZIF-8 NMOFs nanocomposites. The

energy-dispersive X-ray spectroscopy (EDX) mapping images of ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites demonstrate Zn element is well-distributed across the nanoparticles, confirming the relatively homogenous composition. (Supporting Figure S10 and Figure S11)

3.2 *In vitro* study of ZIF-8 NMOFs nanocomposites

After successful preparation of ZIF-8 NMOFs nanocomposites with different sizes, their drug loading and release capabilities were evaluated. DOX, a well-known anticancer drug, was used as a test case. DOX loading was achieved by simply mixing ZIF-8 NMOFs nanocomposites with DOX in an aqueous solution. Because the pore size of ZIF-8 is very small, DOX is physically adsorbed on the surface of ZIF-8 nanocomposite. We found that the drug loading capability of the three prepared ZIF-8 NMOFs nanocomposites was different. ZIF-8 (1.2K) NMOFs nanocomposites show much better DOX loading capacity than ZIF-8 (8K) and ZIF-8 (20K) ones. (Figure 2a-b) When the mixing ratio of ZIF-8 NMOFs nanocomposites to DOX is 1:1, the loading efficiencies (weight of loaded DOX/weight of total DOX) are >97% for ZIF-8 (1.2K) and ZIF-8 (8K) and >87% for ZIF-8 (20K). When the amount of DOX continually increases in the mixture (ZIF-8 to DOX ratios drop to 1:2, 1:4 and 1:8), the loading efficiency drops as the percentage of ZIF-8 NMOFs nanocomposites in the mixture becomes smaller. However, the loading capacity (weight of loaded DOX/weight of ZIF-8) keeps increasing. For example, when the ratio of ZIF-8 NMOFs nanocomposites to DOX is 1:8, every mg of ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) can load 3.85 (385%), 3.14 (314%), and 1.73 (173%) mg of DOX, with loading efficiency of 48%, 39% and 22%, respectively. These values indicate that our fabricated ZIF-8 NMOFs nanocomposites show very high drug loading capacity. Difference of drug loading capacity may be caused by the different crystallinity of different ZIF-8 NMOFs nanocomposites.

Figure 2. a) The loading capacities and b) loading efficiencies of DOX to ZIF-8 NMOFs nanocomposites at different mixing ratios (5 groups of ZIF-8 NMOFs nanocomposites to DOX ratios: 2:1, 1:1, 1:2, 1:4 and 1:8); c-d) The DOX release curves at pH 7.4 (physiological pH value) and pH 5 from ZIF nanocomposites with drug loading capacity of (c) 100 wt% and (d) 10 wt%.

Once confirming that our fabricated ZIF-8 NMOFs nanocomposites display excellent drug loading capacity, we next investigated their release kinetics. ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites with drug loading capacity of 100 wt% (The weight of drug and ZIF-8 is equivalent) and 10 wt% (weight of drug/weight of ZIF-8 = 1:10) were selected for *in vitro* release study. (Figure 2c-d) Under pH 7.4, all ZIF NMOFs nanocomposites can hold DOX molecule relatively firmly for at least 24 hours, with only <15% (drug loading 100 wt%) and <30% (drug loading 10 wt%) of the loaded drugs released to the buffer solutions. However, when pH drops to 5 (the pH value of tumor tissue or lysosome), drug release becomes faster. Interestingly, these as-fabricated ZIF-8 NMOFs nanocomposites display different pH sensitivity. ZIF-8 (1.2K) is found to be more pH sensitive than ZIF-8 (8K) and ZIF-8 (20K). For example, ZIF-8 (1.2K) NMOFs nanocomposites with drug loading capacity of 100 wt%

releases greater 60% of DOX at pH 5, which is much higher than the other two nanocomposites. The possible explanation of the different pH sensitivity is due to the different crystallinity: ZIF (1.2K) NMOFs nanocomposites have less crystallinity than ZIF-8 (8K) and ZIF-8 (20K), resulting in lower stability in acid environments, and thus release of more DOX drug. This explanation was supported by TEM images of ZIF-8 nanocomposites after treatment in pH 7.4 and pH 5 buffer solution. The structure of vast majority of ZIF-8 (1.2k), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites collapses at pH 5, while their structure is relatively stable at pH 7.4, particularly for ZIF-8 (8K) and ZIF-8 (20K); at pH 5, some ZIF-8 (20K) NMOFs nanocomposites can still maintain the structure. (Supporting Figure S12) In consistence with these findings observed from TEM, DLS shows the mean count rate of ZIF-8 (1.2k), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites significantly drops to less than 20 kcps (almost background level) after pH 5 buffer treatment for 2 min. This means that the release of the drug from the MOFs is more efficient at a lower pH value. Overall, ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites display different size, crystallinity, drug loading capacity and pH sensitivity. (Table 1)

Table 1. The summary of size and loading capacity of PAAS and ZIF-8 NMOFs nanocomposites.

	PAAS (1.2K)	PAAS (8K)	PAAS (20K)
PAAS Size (DLS)	105nm	79nm	33nm
ZIF-8 Size (DLS)	190nm	98nm	46nm
ZIF-8 Size (TEM)	200nm	90nm	30nm
Drug Loading Capacity (wt%)	385 wt%	314 wt%	173 wt%

Following the study of the release kinetics, the intracellular delivery of different sizes of ZIF-8 NMOFs nanocomposites loaded with DOX was studied, because the size of nanomaterials can dramatically affect their intracellular delivery efficiency. In this study, we

selected ZIF-8 NMOFs nanocomposites with DOX loading of 10 wt% to investigate the intracellular delivery efficiencies of the three different ZIF-8 NMOFs nanocomposites. The results are shown in Figure 3. It is apparent that the intracellular delivery efficiency is size dependent: ZIF-8 (1.2K) < ZIF-8 (8K) < ZIF-8 (20K). After 4 hours incubation, the HeLa cells treated with ZIF-8 (20K) (46 nm) NMOFs nanocomposites show much stronger fluorescence signal from DOX than those treated with ZIF-8 (1.2K) (190 nm) and ZIF-8 (8K) (98 nm) NMOFs nanocomposites.

Figure 3. a-i) Fluorescence microscopy images of HeLa cells after 4 hours incubation with (a-c) ZIF-8 (1.2K), (d-f) ZIF-8 (8K) and (g-i) ZIF-8 (20K) NMOFs nanocomposites loaded with 10 wt% DOX.

Subsequently, we characterized the HeLa cell viability after incubation with ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) NMOFs nanocomposites for 48 and 72 hours. (Figure 4) Again, we chose ZIF-8 NMOFs nanocomposites with 10 wt% DOX loading for test. The results show that significantly improved delivery efficiency can be achieved with the aid of ZIF-8 NMOFs nanocomposites, particularly with the nanocomposite made from PAAS of molecular weight of 20k Daltons. (Figure 4) This is well-matched with our data that ZIF-8 (20K) enter cells more efficiently than ZIF-8 (1.2K) and ZIF-8 (8K) NMOFs nanocomposites. For ZIF-8 (1.2K) and

ZIF-8 (8K) NMOFs nanocomposites, the drug efficacy is overall comparable to free DOX in cell lines, depending on the concentrations of the drug. However, we expect that the ZIF-8-DOX can realize much better efficacy and smaller side effect in *in vivo* applications due to the enhanced permeability and retention (EPR) effect and the preferable release kinetics of nanomedicine.

Figure 4. The viabilities of HeLa cells after 48 (a) and 72 (b) hours of incubation with free DOX and ZIF-8 (1.2K), ZIF-8 (8K), and ZIF-8 (20K) NMOFs nanocomposites loaded with 10 wt% of DOX.

3.3 *In vivo* study of ZIF-8 NMOFs Nanocomposites

Once we know that ZIF-8 NMOFs nanocomposites have excellent properties and high cell killing efficiency, its application in *in vivo* anticancer therapy was next evaluated. In this study, ZIF-8 (8K) NMOFs nanocomposites were chosen as a drug delivery vector, because of its well-balanced drug loading capacity, pH sensitivity and stability. In order to prolong the material's blood circulation time, PEG (Mw=5000) was conjugated to PAAS (8K) molecule before nanocomposites fabrication. (Scheme 2) (Figure S13) Then for drug loading, 1 mL of 1 mg/mL of DOX was mixed with 1 mL of 1 mg/mL of MOF-PEG nanocomposites for 24 hours. During this process, almost all DOX was able to be loaded to MOF-PEG nanocomposites. This is the advantage of our ZIF-8 nanocomposite. The reason is: PEG is conjugated to PAAS template instead of ZIF-8 nanocrystal and therefore it does not interfere subsequent drug loading.

Scheme 2. Schematic illustration of PEG modified ZIF-8 NMOFs nanocomposites formation using PAAS as a soft template.

After drug loading, the biodistribution of MOF-PEG DOX nanocomposites in mice was investigated by using small animal *in vivo* fluorescence system to detect the fluorescence signal of DOX. (Supporting Figure S15) It was found that DOX can be effectively delivered to the tumor site within 24 hours, demonstrated the very bright DOX fluorescence signal. At 48 hours after injection, the fluorescence intensity in the tumor site further increases, while the fluorescence intensities in major organs including heart, liver, kidney, spleen, and lung start to drop.

Since PEG modified MOF nanocomposites can effectively deliver DOX to tumor sites, it is expected that it can efficiently inhibit tumor growth. To verify this, a group of 5 mice was intravenously injected with MOF-PEG DOX (DOX dose at 2.5 mg/kg) and then the tumor volumes of mice were monitored for 22 days. In addition, for comparison purpose, 3 other groups of mice were injected with PBS, free DOX (DOX), and MOF loaded with DOX but without PEG modification (MOF DOX). The results are shown in Figure 5a. It is clear that the

therapeutic efficacy of free DOX molecules and the DOX delivered by MOF nanocomposites without PEG surface modification is very low, indicating by the rapid growing tumor during the observation period. In great comparison, MOF-PEG DOX constantly exhibits significantly improved therapeutic efficiency: more than 50% tumor reduction comparing with other 3 groups. There is a statistical difference between MOF-PEG DOX and other three groups ($p < 0.05$). Moreover, there is minimal weight loss in the group treated with MOF-PEG DOX (Figure 5b), indicating that the PEG modified MOF with MTX has great therapeutic efficacy with good biocompatibility. In addition, H&E staining of tumor slices were also evaluated. From the H&E staining, higher tumor cell damage is shown in MOF-PEG DOX treated tumor, compared with MOF DOX, DOX and PBS treated groups, which confirms that MOF-PEG DOX has better anti-cancer efficiency (Figure 5c).

Figure 5. *In vivo* anticancer activities: a). Tumor growth curves of 4T1 tumor bearing BALB/C mice after intravenous injection with 1). PBS, 2). DOX loaded by PEG modified ZIF-8 NMOFs nanocomposites (MOF-PEG DOX), 3). DOX loaded by ZIF-8 NMOFs nanocomposites (MOF DOX), 4) free DOX ; b). The body weight evolution of 4T1 tumor-bearing mice at different times after intravenous injection of different materials; c) H&E staining images of tumors slices. Scale bar: 100 μ m.

To investigate the mechanism of MOF-PEG DOX inhibition of tumor growth, immunohistochemistry analysis of Caspase-3, KI-67 and CD31 as well as Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was conducted. (Figure 6) Caspase-3, KI-67 and CD31 are the indicators for apoptosis, cell proliferation and tumor angiogenesis, respectively. In Figure 6, the mean optical density (MOD) for Caspase-3 expression are 0.313 ± 0.001 , 0.300 ± 0.006 , 0.288 ± 0.001 and 0.277 ± 0.004 for MOF-PEG DOX, MOF DOX, DOX and PBS treated groups, respectively. The higher expression of Caspase-3 in

MOF-PEG DOX treated group indicates that MOF-PEG DOX induce higher cell apoptosis than MOF DOX and DOX, thereby causing the death of tumor cells. For quantity analysis, the cell apoptosis was also evaluated by TUNEL, which shows $73.3\pm4.04\%$; $34\pm7\%$; $69.0\pm2.6\%$ and $24.7\pm2.5\%$ apoptosis cells in MOF-PEG DOX, MOF DOX, DOX and PBS treated groups, respectively. These confirm that MOF-PEG DOX can effectively kill tumor cell by inducing cell apoptosis.

Figure 6. Immunohistochemistry (Caspase 3, KI67 and CD31 antibody) and TUNEL images of tumor slices. 4T1 tumor bearing BALB/C mice after intravenous injection with 1). DOX loaded by PEG modified ZIF-8 NMOFs nanocomposites (MOF-PEG DOX), 2). DOX loaded by ZIF-8 NMOFs nanocomposites (MOF DOX), 3) free DOX and 4). PBS. Yellow brown indicates positive; blue indicates negative. Scale bar: 40 μm .

In addition, we evaluated the level of KI-67, which is a key indicator for cell proliferation. Dramatically lowered expression of KI-67 was detected in MOF-PEG DOX treated tumor ($\text{MOD}=0.295\pm0.013$) compared with MOF DOX (0.339 ± 0.013), DOX ($\text{MOD}=0.328\pm0.016$) and PBS ($\text{MOD}=0.345\pm0.008$) treated groups, indicating enhanced inhibition of the cancer cell

proliferation. Finally, we analyzed CD31 protein, which is highly associated with tumor angiogenesis and tumor growth. In Figure 6, lower CD31 expression is presented in the MOF-PEG DOX treated group, revealing that tumor growth was effectively inhibited. Microvascular density (MVD) was also counted (most vascularized area, every slice 5 hot spots were selected), which is highly associated with tumor metastasis and prognosis. The average MVD results are 6.6 ± 1.1 ; 12 ± 1.6 ; 10.4 ± 2.7 and 16.6 ± 2 in MOF-PEG DOX, MOF DOX, DOX and PBS treated groups, respectively. The MVD counting confirms the effectiveness of MOF-PEG DOX for tumor growth inhibition.

Figure 7. H&E staining images of major organs (heart, liver, spleen, lung, and kidney). The mice were treated with DOX loaded by PEG modified ZIF-8 NMOFs nanocomposites, free DOX and PBS at Day 1 and sacrificed at Day 7. Scale bar: 200 μ m.

3.4 Biosafety study of ZIF-8 NMOFs Nanocomposites

Biosafety is one of a major concern for clinical application of nanomedicine; therefore, we finally systematically investigated the toxicity of MOF-PEG DOX. Firstly, histopathological examinations (H&E staining) were conducted to analyze major organs, including heart, liver, spleen, lung and kidney. (Figure 7) From these H&E staining images, no obvious organ damage is shown in DOX and MOF-PEG DOX treated groups. Apparently, histopathological examinations demonstrate MOF-PEG DOX nanocomposites cause minimal toxicity to major organs. Because liver and kidney damage is a very common side-effect of therapeutic drugs, to investigate the biosafety of MOF-PEG DOX, the liver and kidney function (Figure 8) of the treated mice were evaluated by measuring the blood serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine (CRE) and uric acid (UA). From the results, no obvious abnormality is found, indicating that MOF-PEG DOX nanocomposites have low toxicity towards liver and kidney, which is in line with our histopathological results. Since ZIF-8 NMOFs were intravenously injected, these drugs directly interacted with blood. Therefore, blood chemistry analysis was performed. There is also no significant abnormality of the complete blood counts data, including red blood cells (RBC), white blood cells (WBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT) (Figure S16). Overall, all of these toxicity profiles suggest that MOF-PEG DOX have high biosafety for *in vivo* cancer therapy.

Figure 8. Liver function (ALT, AST and ALP) and Kidney function (BUN , CRE and UA) of healthy mice. The mice were treated with (A) PBS, (B) free DOX, (C) PEG modified ZIF-8 NMOFs nanocomposites at Day 1 and sacrificed at Day 7. The normal ranges of ALT, AST, ALP, BUN, CRE and UA are 33.0-99.0, 69.5-210.0, 40.0-190.0, 2.00-7.70, 22.0-97.0 and 20-420, respectively.

4. Conclusion

In summary, we have developed a strategy of using PAAS as a soft template to prepare size controllable and surface modifiable ZIF-8-PAAS nanocomposites in the range of 30-200 nm which is suitable for drug delivery. The as-fabricated nanocomposites have ultra-high drug loading capacity of up to 385 wt%. We also demonstrate that the nanocomposites fabricated from different PAAS nanospheres have different crystallinity, drug loading capacity and release kinetics, and pH sensitivity. Also very importantly, these nanocomposites can be conveniently modified with functional molecules. As a test case, these nanocomposites were functionalized with PEG and employed as vectors to deliver DOX for cancer therapy with greatly enhanced efficacy *in vitro* and *in vivo*. Thus, this work provides a strategy to fabricate NMOFs nanocomposites with size tunability and flexible surface chemistry for various applications.

Associated Content

Supporting information. Figure S1 particle size distribution, Figure S2-S4 SEM images, Figure S5 particle size distribution, Figure S6 Zeta potential, Figure S7 The Fourier transform infrared spectroscopy, Figure S8 the powder X-ray diffraction patterns, Figure S9-S12 TEM, HRTEM

and STEM images, Figure S13 SEM, TEM and XRD, Figure S14 digital image, Figure S15 Biodistribution, Figure S16 the complete blood counts. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Author Information

Corresponding Author

*E-mail Xianfeng.Chen@oxon.org (Michael.Chen@ed.ac.uk); apwjzh@cityu.edu.hk;

Notes

The authors declare no competing financial interest.

ACKNOWLEDGEMENT

The work was financially supported by the General Research Fund of Hong Kong (CityU 11338516 and 11306717), the School of Engineering of University of Edinburgh, the Royal Society Research Grant Scheme RG150564, and the Chengdu University (No. 2081916010 and ARRLKF16-05).

REFERENCES

- (1) Furukawa, H.; Cordova, K.E.; O'Keeffe, M.; Yaghi, O.M. The Chemistry and Applications of Metal-Organic Frameworks. *Science* **2013**, *341*, 1230444.
- (2) Yaghi, O.M.; O'Keeffe, M.; Ockwig, N.W.; Chae, H.K.; Eddaoudi, M.; Kim, J. Reticular Synthesis and The Design of New Materials. *Nature* **2003**, *423*, 705-714.
- (3) Zhou, H.; Long, J.R.; Yaghi, O.M. Introduction to Metal-Organic Frameworks. *Chem. Rev.* **2012**, *112*, 673-674.
- (4) Chae, H.K.; Siberio-Pérez, D.; Kim, J.; Go, Y.; Eddaoudi, M.; Matzger, A.J.; O'Keeffe, M.; Yaghi, O. A Route to High Surface Area, Porosity and Inclusion of Large Molecules in Crystals. *Nature* **2004**, *427*, 523-527.
- (5) Deng, H.; Doonan, C.J.; Furukawa, H.; Ferreira, R.B.; Towne, J.; Knobler, C.B.; Wang, B.; Yaghi, O.M. Multiple Functional Groups of Varying Ratios in Metal-Organic Frameworks. *Science* **2010**, *327*, 846-850.
- (6) Furukawa, H.; Ko, N.; Go, Y.B.; Aratani, N.; Choi, S.B.; Choi, E.; Yazaydin, A.O.; Snurr, R.Q.; O'Keeffe, M.; Kim, J.; Yaghi, O.M. Ultrahigh Porosity in Metal-Organic Frameworks. *Science* **2010**, *329*, 424-428.

- (7) Deng, H.; Grunder, S.; Cordova, K.E.; Valente, C.; Furukawa, H.; Hmadeh, M.; Gándara, F.; Whalley, A.C.; Liu, Z.; Asahina, S.; Kazumori, H.; O'Keeffe, M.; Terasaki, O.; Stoddart, J.F.; Yaghi, O.M. Large-Pore Apertures in a Series of Metal-Organic Frameworks. *Science* **2012**, *336*, 1018-1023.
- (8) DeCoste, J.B.; Peterson, G.W. Metal-Organic Frameworks for Air Purification of Toxic Chemicals. *Chem. Rev.* **2014**, *114*, 5695-5727.
- (9) Li, J.R.; Kuppler, R.J.; Zhou, H.C. Selective Gas Adsorption and Separation in Metal-Organic Frameworks. *Chem. Soc. Rev.* **2009**, *38*, 1477-1504.
- (10) Barea, E.; Montoro, C.; Navarro, J.A. Toxic Gas Removal--Metal-Organic Frameworks for The Capture and Degradation of Toxic Gases and Vapours. *Chem. Soc. Rev.* **2014**, *43*, 5419-5430.
- (11) Suh, M.P.; Park, H.J.; Prasad, T.K.; Lim, D.W. Hydrogen Storage in Metal-Organic Frameworks. *Chem. Rev.* **2012**, *112*, 782-835.
- (12) Eddaoudi, M.; Sava, D.F.; Eubank, J.F.; Adil, K.; Guillerm, V. Zeolite-Like Metal–Organic Frameworks (ZMOFs): Design, Synthesis, and Properties. *Chem. Soc. Rev.* **2015**, *44*, 228-249.
- (13) Yang, Q.; Liu, D.; Zhong, C.; Li, J.R. Development of Computational Methodologies for Metal-Organic Frameworks and Their Application in Gas Separations. *Chem. Rev.* **2013**, *113*, 8261-8323.
- (14) Chaemchuen, S.; Kabir, N.A.; Zhou, K.; Verpoort, F. Metal-Organic Frameworks for Upgrading Biogas via CO₂ Adsorption to Biogas Green Energy. *Chem. Soc. Rev.*, **2015**, *42*, 9304-9332.
- (15) Kreno, L.E.; Leong, K.; Farha, O.K.; Allendorf, M.; Van Duyne, R.P.; Hupp, J.T. Metal-Organic Framework Materials as Chemical Sensors. *Chem. Rev.* **2012**, *112*, 1105-1125.
- (16) Rocha, J.; Carlos, L.D.; Paz, F.A.; Ananias, D. Luminescent Multifunctional Lanthanides-Based Metal-Organic Frameworks. *Chem. Soc. Rev.* **2011**, *40*, 926-940.
- (17) Corma, A.; García, H.; Llabrés i Xamena, F.X. Engineering Metal Organic Frameworks for Heterogeneous Catalysis. *Chem. Rev.* **2010**, *110*, 4606-4655.
- (18) Yoon, M.; Srirambalaji, R.; Kim, K. Homochiral Metal-Organic Frameworks for Asymmetric Heterogeneous Catalysis. *Chem. Rev.* **2012**, *112*, 1196-1231.
- (19) Liu, J.W.; Chen, L.F.; Cui, H.; Zhang, J.Y.; Zhang, L.; Su, C.Y. Applications of Metal-Organic Frameworks in Heterogeneous Supramolecular Catalysis. *Chem. Soc. Rev.* **2014**, *43*, 6011-6061.

- (20) Dhakshinamoorthy, A.; Hermenegildo, H. Catalysis by Metal Nanoparticles Embedded on Metal-Organic Frameworks. *Chem. Soc. Rev.* **2012**, *41*, 5262-5284.
- (21) Horcajada, P.; Gref, R.; Baati, T.; Allan, P.K.; Maurin, G.; Couvreur, P.; Férey, G.; Morris, R.E.; Serre, C. Metal-Organic Frameworks in Biomedicine. *Chem. Rev.* **2012**, *112*, 1232-1268.
- (22) McKinlay, A.C.; Morris, R.E.; Horcajada, P.; Férey, G.; Gref, R.; Couvreur, P.; Serre, C. BioMOFs: Metal-Organic Frameworks for Biological and Medical Applications. *Angew. Chem. Int. Ed.* **2010**, *49*, 6260-6266.
- (23) Kievit, F.M.; Zhang, M. Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery across Biological Barriers. *Adv. Mater.* **2011**, *23*, H217-H247.
- (24) Wang, D.; Zhou, J.; Chen, R.; Shi, R.; Xia, G.; Zhou, S.; Liu, Z.; Zhang, N.; Wang, H.; Guo, Z.; Chen, Q. Magnetically Guided Delivery of DHA and Fe Ions for Enhanced Cancer Therapy Based on pH-Responsive Degradation of DHA-Loaded Fe₃O₄@C@MIL-100(Fe) Nanoparticles. *Biomaterials*, **2016**, *107*, 88-101.
- (25) Wang, D.; Zhou, J.; Chen, R.; Shi, R.; Zhao, G.; Xia, G.; Li, R.; Liu, Z.; Tian, J.; Wang, H.; Guo, Z.; Wang, H.; Chen, Q. Controllable Synthesis of Dual-MOFs Nanostructures for pH-Responsive Artemisinin Delivery, Magnetic Resonance and Optical Dual-Model Imaging-Guided Chemo/Photothermal Combinational Cancer Therapy. *Biomaterials*, **2016**, *100*, 27-40.
- (26) Zheng, H.; Zhang, Y.; Liu, L.; Wan, W.; Guo, P.; Nyström, A.M.; Zou, X. One-Pot Synthesis of Metal-Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery. *J. Am. Chem. Soc.* **2016**, *138*, 962-968.
- (27) Yang, Y.; Liu, J.; Liang, C.; Feng, L.; Fu, T.; Dong, Z.; Chao, Y.; Li, Y.; Lu, G.; Chen, M.; Liu, Z. Nanoscale Metal-Organic Particles with Rapid Clearance for Magnetic Resonance Imaging-Guided Photothermal Therapy. *ACS Nano*, **2016**, *10*, 2774-2781.
- (28) Liu, J.; Yang, Y.; Zhu, W.; Yi, X.; Dong, Z.; Xu, X.; Chen, M.; Yang, K.; Lu, G.; Jiang, L.; Liu, Z. Nanoscale Metal-Organic Frameworks for Combined Photodynamic&Radiation Therapy in Cancer Treatment. *Biomaterials*, **2016**, *97*, 1-9.
- (29) Horcajada, P.; Serre, C.; Vallet-Regí, M.; Sebban, M.; Taulelle, F.; Férey, G. Metal-Organic Frameworks as Efficient Materials for Drug Delivery. *Angew. Chem. Int. Ed.* **2006**, *45*, 5974-5978.
- (30) Horcajada, P.; Serre, C.; Maurin, G.; Ramsahye, N.A.; Balas, F.; Vallet-Regí, M.; Sebban, M.; Taulelle, F.; Férey, G. Flexible Porous Metal-Organic Frameworks for a Controlled Drug Delivery. *J. Am. Chem. Soc.* **2008**, *130*, 6774-6780.

- (31) deKrafft, K.E.; Xie, Z.; Cao, G.; Tran, S.; Ma, L.; Zhou, O.Z.; Lin, W. Iodinated Nanoscale Coordination Polymers as Potential Contrast Agents for Computed Tomography. *Angew. Chem. Int. Ed.* **2009**, *48*, 9901-9904.
- (32) Allendorf, M.D.; Bauer, C.A.; Bhakta, R.K.; Houk, R.J. Luminescent Metal-Organic Frameworks. *Chem. Soc. Rev.* **2009**, *38*, 1330-1352.
- (33) Zhuang, J.; Kuo, C.; Chou, L.; Liu, D.; Weerapana, E.; Tsung, C. Optimized Metal-Organic-Framework Nanospheres for Drug Delivery: Evaluation of Small-Molecule Encapsulation. *ACS Nano*. **2014**, *8*, 2812-2819.
- (34) He, C.; Lu, K.; Liu, D.; Lin, W. Nanoscale Metal-Organic Frameworks for The Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells. *J. Am. Chem. Soc.* **2014**, *136*, 5181-5184.
- (35) Zhao, D.; Tan, S.; Yuan, D.; Lu, W.; Rezenom, Y.H.; Jiang, H.; Wang, L.; Zhou, H. Surface Functionalization of Porous Coordination Nanocages via Click Chemistry and Their Application in Drug Delivery. *Adv. Mater.* **2011**, *23*, 90-93.
- (36) Agostoni, V.; Chalati, T.; Horcajada, P.; Willaime, H.; Anand, R.; Semiramoth, N.; Baati, T.; Hall, S.; Maurin, G.; Chacun, H.; Bouchemal, K.; Martineau, C.; Taulelle, F.; Couvreur, P.; Rogez-Kreuz, C.; Clayette, P.; Monti, S.; Serre, C.; Gref, R. Towards an Improved Anti-HIV Activity of NRTI via Metal-Organic Frameworks Nanoparticles. *Adv. Healthcare Mater.* **2013**, *2*, 1630-1637.
- (37) Wu, Y.; Zhou, M.; Li, S.; Li, Z.; Li, J.; Wu, A.; Li, G.; Li, F.; Guan, X. Magnetic Metal-Organic Frameworks: γ -Fe₂O₃@MOFs via Confined in situ Pyrolysis Method for Drug Delivery. *Small* **2014**, *10*, 2927-2936.
- (38) Horcajada, P.; Chalati, T.; Serre, C.; Gillet, B.; Sebrie, C.; Baati, T.; Eubank, J.F.; Heurtaux, D.; Clayette, P.; Kreuz, C.; Chang, J.; Hwang, Y.K.; Marsaud, V.; Bories, P.; Cynober, L.; Gil, S.; Férey, G.; Couvreur, P.; Gref, R. Porous Metal-Organic-Framework Nanoscale Carriers as a Potential Platform for Drug Delivery and Imaging. *Nat. Mater.* **2010**, *9*, 172-178.
- (39) Park, J.; Jiang, Q.; Feng, D.; Mao, L.; Zhou, H.C. Size-Controlled Synthesis of Porphyrinic Metal-Organic Framework and Functionalization for Targeted Photodynamic Therapy. *J. Am. Chem. Soc.* **2016**, *138*, 3518-3525.
- (40) Bellido, E.; Hidalgo, T.; Lozano, M.V.; Guillevis, M.; Simón-Vázquez, R.; Santander-Ortega, M.J.; González-Fernández, Á.; Serre, C.; Alonso, M.J.; Horcajada, P. Heparin-Engineered Mesoporous Iron Metal-Organic Framework Nanoparticles: Toward Stealth Drug Nanocarriers. *Adv. Healthcare Mater.* **2015**, *4*, 1246-1257.

(41) Ren, H.; Zhang, L.; An, J.; Wang, T.; Li, L.; Si, X.; He, L.; Wu, X.; Wang, C.; Su, Z. Polyacrylic Acid@zeolitic Imidazolate Framework-8 Nanoparticles with Ultrahigh Drug Loading Capability for pH-Sensitive Drug Release. *Chem. Commun.* **2014**, *50*, 1000-1002.

Table of Content (TOC)

Supporting Information

Size Controllable and Surface Tunable Zeolitic Imidazolate Framework-8 (ZIF-8)-Poly(acrylic acid sodium salt) (PAAS) Nanocomposites for pH Responsive Drug Release and Enhanced *In Vivo* Cancer Treatment

Li Yan,^{▽,†} Xianfeng Chen,^{*,‡} Zhigang Wang,⁺ Xiujuan Zhang,[‡] Xiaoyue Zhu,[†] Mengjiao Zhou,[‡] Wei Chen,[†] Longbiao Huang,[†] Vellaisamy A.L. Roy,[†] Peter K.N. Yu, Guangyu Zhu,⁺ Wenjun Zhang^{*,†}

[▽] Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics (SIIA), Chengdu University, Chengdu, Sichuan, PR China

[‡] Institute for Bioengineering, School of Engineering, The University of Edinburgh, Mayfield Road, Edinburgh EH9 3JL, United Kingdom.

[†] Center of Super-Diamond and Advanced Films (COSDAF) and Department of Materials Science and Engineering, City University of Hong Kong, Hong Kong SAR

[§] Department of Physics, City University of Hong Kong, Hong Kong SAR

[‡] Functional Nano & Soft Materials Laboratory (FUNSOM) and Collaborative Innovation Center of Suzhou Nano Science and Technology, Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, Jiangsu, PR China

⁺ Department of Chemistry, City University of Hong Kong, Hong Kong SAR

Corresponding authors:

Xianfeng.Chen@oxon.org (Michael.Chen@ed.ac.uk); apwjzh@cityu.edu.hk

Figure S1. Particle size distributions of (a) PAAS nanospheres (1.2K), (b) PAAS nanospheres (8K), and (c) PAAS nanospheres (20K).

Figure S2. (a, b) SEM images of PAAS nanospheres (8K).

Figure S3. (a, b) SEM images of PAAS nanospheres (20K). We were unable to capture SEM images of PAAS nanospheres with M_w of 1.2K. The reason may be that the nanospheres made from PAAS with M_w of 1.2K are extremely unstable, and the nanosphere structure collapses during the drying period.

Figure S4. SEM images of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) nanocomposites.

Figure S5. Particle size distributions of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) nanocomposites.

Figure S6. Zeta potential of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) nanocomposites.

Figure S7. The Fourier transform infrared spectroscopy of ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) nanocomposites.

Figure S8. The powder X-ray diffraction patterns of ZIF-8 (1.2K), ZIF-8 (8K) and ZIF-8 (20K) nanocomposites, as well as ZIF-8.

Figure S9. HRTEM images of (a) ZIF-8 (1.2K), (b) ZIF-8 (8K), and (c) ZIF-8 (20K) nanocomposites.

Figure S10. (a,c) Scanning TEM images of ZIF-8 (1.2K) nanocomposites, and (b,d) corresponding EDX mapping images of Zn.

Figure S11. (a,c) Scanning TEM images of ZIF-8 (8K) nanocomposites, and (b,d) corresponding EDX mapping images of Zn.

Figure S12. TEM images of (a), (d) ZIF-8 (1.2K); (b), (e) ZIF-8 (8K), and (c), (f) ZIF-8 (20K) nanocomposites after 2 hours of (a-c) pH=7.4 PBS and (d-f) pH=5.0 buffer solution treatment; (f): For ZIF-8 (20K), after 2 hours treatment at pH of 5.0, a very small number of particles can be observed.

Figure S13. Characterization of PEG modified ZIF-8 NMOFs nanocomposites: (a) SEM, (b) TEM and (c) XRD Pattern.

Figure S14. The demonstration of successful conjugation of PEG to ZIF-8 nanocomposite. (In order to demonstrate successful conjugation of PEG to ZIF nanocomposites, we labelled PEG with FITC to track PEG molecules after reaction. In the experiment, FITC labelled PEG molecules were mixed with ZIF-8 nanocomposites; after reaction, the nanocomposites were centrifuged. If PEG was not successfully conjugated to the nanocomposites, the fluorescent PEG molecules would be remained in the solvent. It was found that almost all fluorescence signal was from the precipitated ZIF-8 NMOFs nanocomposites, indicating the successful conjugation of PEG to ZIF-8 nanocomposites.)

Figure S15. Biodistribution of MOF-PEG DOX. (Signal from Dox)

Figure S16. The complete blood counts data: RBC, WBC, HGB, HCT, MCV, MCH, MCHC and PLT. The mice were treated with (A) PBS, (B) free DOX, (C) PEG modified ZIF-8 nanocomposites at Day 1 and sacrificed at Day 7. The normal ranges of RBC, WBC, HGB, HCT, MCV, MCH, MCHC and PLT are 2.20-15.00, 2.3-31.6, 40-174, 0.200-0.400, 44.0-66.5, 13.0-23.0, 270-520 and 270-1100, respectively.